LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced the upcoming presentation of research demonstrating that INNO-206 in combination with either doxorubicin or a novel albumin-binding methotrexate drug induced complete tumor remissions in animal models of human pancreatic cancer. The results will be presented at the American Association for Cancer Research (AACR) 2012 Annual Meeting on Monday, April 2, 2012 in Chicago, Illinois. CytRx holds the worldwide rights to INNO-206, which is a tumor-targeted albumin-binding drug incorporating the widely used chemotherapeutic agent doxorubicin.
